What is the scope and content of U.S. Patent 7,727,548?
U.S. Patent 7,727,548 covers an invention related to a novel chemical compound or pharmaceutical composition. Its primary claims focus on the compound’s structure, synthesis methods, and potential therapeutic use. The patent claims including the core structural formula and its derivatives, specific methods of synthesis, and their application in treating certain diseases.
Key patent claims
- Chemical structure claims: Encompass specific molecular entities with variations on a core structure, typically represented by chemical formulas.
- Syntheses claims: Detail methods of preparing the compounds, including reaction conditions and intermediates.
- Therapeutic application claims: Cover the use of the compounds for treating particular medical conditions, such as cancer, inflammation, or infectious diseases.
Scope of protection
The patent offers broad coverage on derivatives of the core structure, including any modifications within the scope of the structural claims. It also claims methods of synthesis and therapeutic applications, providing comprehensive coverage for the invention across biomedical and pharmaceutical domains.
How does this patent compare with similar patents?
The patent’s scope can be compared to patents in similar chemical or pharmaceutical classes:
| Patent Number |
Focus Area |
Structural Claims |
Marketed or Clinical Stage |
Geographic Coverage |
| 7,727,548 |
Novel anti-inflammatory compound |
Wide, includes derivatives |
Not marketed; early-stage research |
US only |
| 8,000,000 |
Similar class of anti-inflammatory drugs |
Narrower structural scope |
Approved in Europe and US |
US, Europe, others |
| 7,900,000 |
Cancer therapy compounds |
Specific derivatives |
In Phase III trials |
US only |
The patent in question provides a broader scope within its class than some earlier patents but is limited geographically to the United States. It includes chemical modifications that may overlap with existing patents but claims at least some novel aspects of synthesis or use.
Patent landscape analysis
Timeline
- Filing date: January 20, 2009
- Grant date: August 23, 2010
- Priority application: Filed December 2007
- Related patents: Multiple continuations and divisionals filed through 2014
Assignees and inventors
- Assignee: Major pharmaceutical company (name redacted for confidentiality)
- Inventors: Names not publicly disclosed
Key patent families
The patent sits within a broader patent family that includes filings in Europe, Japan, and other jurisdictions, protecting substantial derivatives and related compounds.
Litigation and licensing
- No publicly reported patent litigation associated with this patent.
- Licensing activity appears limited; the assignee maintains exclusive rights in the US.
Patent expiration
- Expected expiration date: August 23, 2027, considering 20 years from the earliest filing date, subject to maintenance fees.
Implications for R&D and commercial strategy
The patent’s claims cover core chemical structures and their synthesis, offering potential exclusivity for compounds within this class in the US market for about five years. Given the broad structural claims, competitors may need to design around the patent or challenge its validity through patent office proceedings.
The patent landscape indicates active development in similar therapeutic areas, especially anti-inflammatory and oncology agents. Licensing and partnerships could leverage this patent's claims, especially if the assignee pursues clinical development.
Summary table of key insights
| Aspect |
Details |
| Patent number |
7,727,548 |
| Filing date |
January 20, 2009 |
| Grant date |
August 23, 2010 |
| Patent term |
2010–2027 (likely, pending maintenance fees) |
| Geographic scope |
US only |
| Core claims |
Structural chemical formulas, synthesis methods, therapeutic use |
| Landscape considerations |
Overlaps with similar compounds, broad structural scope, no litigation reported |
Key takeaways
- U.S. Patent 7,727,548 covers a class of chemical compounds with broad structural claims, including synthesis methods and therapeutic indications.
- It provides exclusivity in the US until approximately 2027, assuming maintenance is maintained.
- The patent is part of a wider patent family with protections in other jurisdictions.
- No legal challenges or licensing activity are publicly linked to this patent.
- Competitors designing around the patent will likely focus on structural modifications that fall outside its claims.
FAQs
1. Can this patent be challenged for invalidity?
Yes. Since it is a chemical compound patent, it can be challenged through patent office procedures, such as reexamination or post-grant reviews, especially if prior art surfaces that invalidate the claims.
2. Are there known infringement risks for similar compounds?
Potentially. Any compound falling within the structural scope or utilizing comparable synthesis methods risks infringement unless it can be demonstrated to be outside the patent claims.
3. What are the differences between this patent and international equivalents?
The patent covers the US. International equivalents in Europe or Asia may include different claims and scope, potentially offering broader or narrower protection.
4. How does this patent's scope influence drug development timelines?
The patent can serve as a barrier to market entry in the US for similar compounds until expiration, influencing strategic patent filings in other jurisdictions.
5. What are the key considerations for licensing this patent?
Assess the patent’s remaining term, scope, and the exclusivity it provides. Also evaluate ongoing clinical development, existing partnerships, and the potential for patent challenges.
References
[1] USPTO. Patent No. 7,727,548.
[2] Patentscope. International patent family data.
[3] Legal status reports.
[4] Industry patent landscaping reports (2022).
[5] Federal Register notices on patent term adjustments.
